Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Michiels S, et al. Among authors: barinoff j. Ann Oncol. 2016 Jun;27(6):1029-1034. doi: 10.1093/annonc/mdw132. Epub 2016 Mar 8. Ann Oncol. 2016. PMID: 26961151 Free article.
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. von Minckwitz G, et al. Among authors: barinoff j. Eur J Cancer. 2011 Oct;47(15):2273-81. doi: 10.1016/j.ejca.2011.06.021. Epub 2011 Jul 7. Eur J Cancer. 2011. PMID: 21741829 Clinical Trial.
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Lübbe K, Marmé F, Maass N, von Minckwitz G, Grischke EM, Müller V, Schmidt M, Gerber B, Kümmel S, Schumacher C, Krabisch P, Seiler S, Thill M, Nekljudova V, Loibl S. Bischoff J, et al. Among authors: barinoff j. Anticancer Drugs. 2019 Apr;30(4):394-401. doi: 10.1097/CAD.0000000000000722. Anticancer Drugs. 2019. PMID: 30875348 Clinical Trial.
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer JU, Budczies J, Mehta KM, von Minckwitz G. Denkert C, et al. Among authors: barinoff j. Ann Oncol. 2013 Nov;24(11):2786-93. doi: 10.1093/annonc/mdt350. Epub 2013 Aug 22. Ann Oncol. 2013. PMID: 23970015 Free article. Clinical Trial.
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S. von Minckwitz G, et al. Among authors: barinoff j. J Clin Oncol. 2013 Oct 1;31(28):3531-9. doi: 10.1200/JCO.2012.47.2167. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980081 Clinical Trial.
Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study.
Maass N, Harbeck N, Mundhenke C, Lerchenmüller C, Barinoff J, Lück HJ, Ettl J, Aktas B, Kümmel S, Rösel S, Wagner S, Müller L, Bischoff J, Lübbe K, Schwedler K, Schmidt M, Bauerschlag D, Nekljudova V, von Minckwitz G, Loibl S; German Breast Group. Maass N, et al. Among authors: barinoff j. J Cancer Res Clin Oncol. 2013 Dec;139(12):2047-56. doi: 10.1007/s00432-013-1518-x. Epub 2013 Sep 27. J Cancer Res Clin Oncol. 2013. PMID: 24072232 Clinical Trial.
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.
von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn BV, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching PA, Karn T, Müller V, Jackisch C, Denkert C. von Minckwitz G, et al. Among authors: barinoff j. Clin Cancer Res. 2013 Aug 15;19(16):4521-31. doi: 10.1158/1078-0432.CCR-12-3628. Epub 2013 Jun 27. Clin Cancer Res. 2013. PMID: 23812670
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Müller V. Witzel I, et al. Among authors: barinoff j. Breast Cancer Res Treat. 2010 Sep;123(2):437-45. doi: 10.1007/s10549-010-1030-9. Epub 2010 Jul 10. Breast Cancer Res Treat. 2010. PMID: 20623180 Clinical Trial.
40 results